Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TEMPE, Ariz., May 21, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), announced that at the Company's Annual Meeting of Stockholders held...
-
TEMPE, Ariz., May 14, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics(Nasdaq:CAPS) is scheduled to make a presentation at the Rodman & Renshaw 6th Annual Global Healthcare Conference, Grosvenor...
-
TEMPE, Ariz., May 12, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today it has completed a limited analysis of a subset of data from the second of its two ongoing...
-
TEMPE, Ariz., March 5, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (the "Company") (Nasdaq:CAPS) today announced it received a letter on March 4, 2010 from The Nasdaq Stock Market notifying the...
-
TEMPE, Ariz., March 2, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today it has completed a limited analysis of a subset of data from one of its two ongoing AZX100 Phase 2a...
-
TEMPE, Ariz., Feb. 17, 2010 (GLOBE NEWSWIRE) -- OrthoLogic Corp., d/b/a Capstone Therapeutics (Nasdaq:CAPS) (the Company) announced today that it intends to propose at its 2010 Annual Meeting of...
-
TEMPE, Ariz., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company") will host a conference call and webcast on Wednesday, February 17,...
-
TEMPE, Ariz., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the 3rd Annual European Life Science CEO Forum, SIX Swiss Exchange,...
-
TEMPE, Ariz., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Biotech Showcase 2010 at the Marines' Memorial Club & Hotel, 609...
-
TEMPE, Ariz., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for its AZX100 Phase 2 clinical trial in dermal scarring following...